Bjoern Moosmann

发表

Development and validation of an LC-MS/MS method for quantification of Δ9-tetrahydrocannabinolic acid A (THCA-A), THC, CBN and CBD in hair.

V. Auwärter, B. Moosmann, Nadine Roth, 2013, Journal of mass spectrometry : JMS.

Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples.

V. Angerer, V. Auwärter, B. Moosmann, 2017, Drug testing and analysis.

Metabolites of synthetic cannabinoids in hair—proof of consumption or false friends for interpretation?

V. Angerer, V. Auwärter, M. Hermanns-Clausen, 2016, Analytical and Bioanalytical Chemistry.

Stability of 11 prevalent synthetic cannabinoids in authentic neat oral fluid samples: glass versus polypropylene containers at different temperatures.

V. Auwärter, B. Moosmann, S. Kneisel, 2013, Drug testing and analysis.

Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples.

D. Rentsch, M. Kassiou, V. Angerer, 2018, Drug testing and analysis.

Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism.

V. Auwärter, B. Moosmann, S. Kneisel, 2013, Journal of mass spectrometry : JMS.

Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites

V. Auwärter, L. Huppertz, B. Moosmann, 2015, Forensic Toxicology.

Immunoassay screening in urine for synthetic cannabinoids – an evaluation of the diagnostic efficiency

C. Schlögl, M. Wagner, V. Angerer, 2017, Clinical chemistry and laboratory medicine.

Designer Benzodiazepines: Another Class of New Psychoactive Substances.

V. Auwärter, Bjoern Moosmann, 2018, Handbook of experimental pharmacology.

Reply to Restolho et al. 'Contactless decontamination of hair samples: cannabinoids'.

V. Auwärter, Bjoern Moosmann, 2017, Drug testing and analysis.

Hair analysis for Δ(9) -tetrahydrocannabinolic acid A (THCA-A) and Δ(9) -tetrahydrocannabinol (THC) after handling cannabis plant material.

V. Auwärter, N. Roth, Bjoern Moosmann, 2016, Drug testing and analysis.

Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8.

S. Knasmüller, V. Auwärter, M. Mišík, 2014, Toxicology and applied pharmacology.

Designer benzodiazepines: A new challenge

L. King, V. Auwärter, B. Moosmann, 2015, World psychiatry : official journal of the World Psychiatric Association.

Inhomogeneities in herbal mixtures: a serious risk for consumers

V. Angerer, V. Auwärter, Bjoern Moosmann, 2014, Forensic Toxicology.

Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples.

V. Angerer, V. Auwärter, L. Huppertz, 2018, Drug testing and analysis.

LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows

V. Auwärter, N. Butlin, B. Moosmann, 2013, Analytical and Bioanalytical Chemistry.

Reply to 'Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA'.

V. Angerer, V. Auwärter, B. Schwarze, 2016, Journal of analytical toxicology.

Separation and structural characterization of the new synthetic cannabinoid JWH-018 cyclohexyl methyl derivative "NE-CHMIMO" using flash chromatography, GC-MS, IR and NMR spectroscopy.

V. Angerer, V. Auwärter, F. Westphal, 2016, Forensic science international.

In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stability.

V. Angerer, V. Auwärter, S. Brandt, 2017, Drug testing and analysis.

Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3yl]-(4-methylnaphthalen-1-yl)methanone using GC-MS, NMR analysis and a flash chromatography system.

V. Brecht, V. Auwärter, U. Girreser, 2012, Forensic science international.

5F-Cumyl-PINACA in ‘e-liquids’ for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA

V. Angerer, V. Auwärter, F. Franz, 2018, Forensic Toxicology.

Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics.

V. Auwärter, A. Buchwald, L. Huppertz, 2013, Journal of mass spectrometry : JMS.

Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.

V. Auwärter, B. Moosmann, P. Bisel, 2014, Drug testing and analysis.

Development of a non-radioactive mass spectrometry-based binding assay at the μ-opioid receptor and its application for the determination of the binding affinities of 17 opiates/opioids as well as of the designer opioid isotonitazene and five further 2-benzylbenzimidazoles.

B. Moosmann, M. Volz, Bjoern Moosmann, 2022, Analytica chimica acta.

New psychoactive substances—Designer benzodiazepines

V. Auwärter, Maurice Wilde, Bjoern Moosmann, 2021 .

Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864).

V. Angerer, V. Auwärter, B. Moosmann, 2019, Drug testing and analysis.

Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine.

V. Auwärter, L. Huppertz, B. Moosmann, 2018, Drug testing and analysis.

Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam.

V. Auwärter, L. Huppertz, B. Moosmann, 2016, Journal of mass spectrometry : JMS.

Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine

V. Auwärter, L. Huppertz, Sascha Ferlaino, 2013, Forensic Toxicology.

Cross reactivity of the CEDIA and HEIA benzodiazepine kits for 29 designer benzodiazepines and tofisopam.

Bjoern Moosmann, Joana Erdmann, 2021, Drug testing and analysis.

Novel Receptor-Binding-Based Assay for the Detection of Opioids in Human Urine Samples.

B. Moosmann, Maja Bergerhoff, Bjoern Moosmann, 2023, Analytical chemistry.

Hair analysis for THCA-A, THC and CBN after passive in vivo exposure to marijuana smoke.

V. Auwärter, N. Roth, Bjoern Moosmann, 2014, Drug testing and analysis.

Hair analysis of synthetic cannabinoids: does the handling of herbal mixtures affect the analyst’s hair concentration?

V. Angerer, M. Neukamm, V. Auwärter, 2014, Forensic Toxicology.

Hair analysis for JWH-018, JWH-122, and JWH-210 after passive in vivo exposure to synthetic cannabinoid smoke

M. Neukamm, V. Auwärter, B. Moosmann, 2014, Forensic Toxicology.

Finding cannabinoids in hair does not prove cannabis consumption

V. Auwärter, N. Roth, Bjoern Moosmann, 2015, Scientific Reports.

Cannabinoid findings in children hair - what do they really tell us? An assessment in the light of three different analytical methods with focus on interpretation of Δ9-tetrahydrocannabinolic acid A concentrations.

F. Pragst, V. Auwärter, M. Hastedt, 2015, Drug testing and analysis.

Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics.

V. Auwärter, A. Buchwald, L. Huppertz, 2013, Journal of mass spectrometry : JMS.

Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.

V. Auwärter, P. Bisel, Bjoern Moosmann, 2014, Drug testing and analysis.

Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2.

P. Mackenzie, Pei H. Cui, C. Dunstan, 2016, The international journal of biochemistry & cell biology.